Skip to main content
    K

    Korro Bio, Inc. (KRRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.32
    -0.39 (-3.07%)

    Market Cap: $174.45M

    Last updated: Nov 17, 2026 at 4:34 PM ET

    Korro Bio, Inc. (KRRO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Korro Bio (KRRO) has a market cap of $174.45M and an enterprise value of $172.69M. It kept -8214.47% of revenue as net income over the last 12 months. Its share count is up 90.25% from a year earlier.

    Total Valuation

    Enterprise value is 1.01% below the market cap, as cash exceeds debt.

    Market Cap$174.45M
    Enterprise Value$172.69M
    Latest price (Nov 17, 2026)$12.32

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.41% in the quarter ended Sep 30, 2026 and grew 38.58% a year over 2 years.

    Shares Outstanding17.87M
    Shares Change (YoY)+90.25%
    Shares Change (QoQ)+1.41%
    Share Count Growth (2Y CAGR)+38.58%

    Valuation Ratios

    Sales and book value multiples are 170.4x and 2.5x.

    P/S Ratio170.4x
    Forward P/S178.1x
    P/B Ratio2.5x

    Price Statistics

    The stock is up 102.97% over 52 weeks and trades 4.05% above its 50-day average.

    Beta (1Y)1.66
    52-Week Change+102.97%
    1-Month Change+38.27%
    3-Month Change-11.68%
    6-Month Change+34.64%
    Total Return (1Y)+102.97%
    Total Return (3Y CAGR)-31.88%
    Return vs SPY (1Y)+86.51%
    Max Drawdown (1Y)-42.32%
    Max Drawdown (3Y)-94.13%
    Sharpe Ratio (1Y)0.80
    Correlation with SPY (1Y)0.26
    50-Day Average$11.84
    200-Day Average$12.16
    52-Week Range$5.20 to $17.35
    RSI (14 Days)45.0
    Average Volume (20 Days)222.30K

    Price chart

    Financial Position

    Current assets cover 7.30x current liabilities, and total debt is 0.44x shareholder equity.

    Current Ratio7.30x
    Quick Ratio7.30x
    Debt / Equity0.44x

    Returns and Efficiency

    Return on invested capital is -82.82% over the last 12 months, against a 5-year average of -92.11%.

    Return on Equity (ROE)-120.09%
    Return on Assets (ROA)-71.65%
    Return on Invested Capital (ROIC)-82.82%
    Return on Capital Employed (ROCE)-78.85%
    ROA (5Y Average)-60.25%
    ROIC (5Y Average)-92.11%
    Asset Turnover0.01x

    Scores

    KRRO has an Altman Z-Score of -3.52, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-3.52
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $1.29M over the last 12 months is down 82.47% from the 12 months before.

    Revenue$1.29M
    Revenue Growth (YoY)-82.47%
    Gross Profit$1.29M
    Operating Income-$109.40M
    Pretax Income-$105.03M
    Net Income-$106.13M
    EBITDA-$103.31M
    EBIT-$105.03M
    Reported EPS (TTM)-$5.39

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 59.66% of the $148.12M in total assets.

    Cash and Equivalents$40.22M
    Total Debt$38.45M
    Net Cash$1.76M
    Net Cash Per Share$0.10
    Working Capital$94.01M
    Shareholder Equity$88.37M
    Book Value Per Share$4.95
    Total Assets$148.12M
    Total Liabilities$59.75M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $169.00K of capital spending, operating cash flow left -$63.87M of free cash flow.

    Operating Cash Flow-$63.70M
    Capital Expenditures$169.00K
    Free Cash Flow-$63.87M
    FCF Per Share-$4.34
    Depreciation and Amortization$1.79M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -8467.34%.

    Gross Margin100.00%
    Operating Margin-8467.34%
    Pretax Margin-8129.41%
    Net Margin-8214.47%
    EBITDA Margin-7996.05%
    EBIT Margin-8129.41%
    FCF Margin-4943.81%

    Growth

    Revenue Growth (5Y CAGR)-29.61%
    Book Value Per Share Growth (2Y CAGR)-49.18%
    Tangible Book Per Share Growth (2Y CAGR)-49.18%

    Revenue and profit by year

    Dividends and Yields

    KRRO does not pay a dividend. Its free cash flow yield is -29.02%.

    FCF Yield-29.02%
    Buyback Yield-38.74%
    Shareholder Yield-38.74%

    Stock Splits

    The last split was a 1-for-50 reverse split on Nov 6, 2023.

    Last Split DateNov 6, 2023
    Split TypeReverse split
    Split Ratio1:50

    Peer Position

    Against 8 similar companies, KRRO has the 2nd highest P/S.

    P/S Ratio170.4x vs 6.3x median
    ROIC-82.82% vs -40.30% median
    Revenue Growth (Trailing 4 Quarters, YoY)-82.47% vs +2.54% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -77.02% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-77.02%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About KRRO

    What is KRRO's market cap?

    Korro Bio has a market cap of $174.45M. Its enterprise value, which adds debt and subtracts cash, is $172.69M.

    How many shares of KRRO are outstanding?

    Korro Bio has 17.87M shares outstanding. The count is up 90.25% from a year earlier.

    Does KRRO pay a dividend?

    No. Korro Bio does not pay a dividend.

    How much debt does KRRO have?

    Korro Bio has $38.45M of total debt and $40.22M of cash and equivalents, a net cash position of $1.76M.